Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-20-071630
Filing Date
2020-03-12
Accepted
2020-03-12 16:30:58
Documents
11
Period of Report
2020-04-23
Effectiveness Date
2020-03-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A d812873ddef14a.htm DEF 14A 1105663
2 GRAPHIC g812873g11f79.jpg GRAPHIC 95796
3 GRAPHIC g812873g11y77.jpg GRAPHIC 26592
4 GRAPHIC g812873g12c33.jpg GRAPHIC 58864
5 GRAPHIC g812873g13z53.jpg GRAPHIC 117514
6 GRAPHIC g812873g21j11.jpg GRAPHIC 24658
7 GRAPHIC g812873g22h30.jpg GRAPHIC 28958
8 GRAPHIC g812873g49a18.jpg GRAPHIC 25012
9 GRAPHIC g812873g56z83.jpg GRAPHIC 16586
10 GRAPHIC g812873g57f70.jpg GRAPHIC 22487
11 GRAPHIC g812873g81n51.jpg GRAPHIC 47766
  Complete submission text file 0001193125-20-071630.txt   1747112
Mailing Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862
Business Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 978 671-8001
Lantheus Holdings, Inc. (Filer) CIK: 0001521036 (see all company filings)

EIN.: 352318913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36569 | Film No.: 20709217
SIC: 2835 In Vitro & In Vivo Diagnostic Substances